What will Insilico Medicine reveal about ISM6331 at the ESMO 2026 Congress?
Insilico Medicine’s first human data for ISM6331 will arrive as clinical interest in TEAD inhibition is accelerating. The presentation must show whether the AI-designed molecule can combine credible antitumor activity with a dose and safety profile suitable for further development.
